The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
Open accessAbstract
Background IL-5, a mediator of eosinophil activity, is an important potential treatment target in patients with uncontrolled asthma. The efficacy of reslizumab, a humanized anti-human IL-5 monoclonal antibody, has been characterized in patients with blood eosinophils ≥ 400 cells/μL. This study further characterizes the efficacy and safety of reslizumab in patients with poorly-controlled asthma, particularly those with eosinophils < 400 cells/μL. Methods Patients were randomly assigned to intravenous reslizumab 3.0 mg/kg or placebo once every 4 weeks for 16 weeks. The primary end point was the change in FEV 1 from baseline to week 16. Secondary measures included Asthma Control Questionnaire-7 (ACQ-7) scores, use of short-acting β-agonists (SABAs), and FVC. Results Four hundred ninety-two patients received ≥ 1 dose of placebo (n = 97) or reslizumab (n = 395). In the overall population, mean FEV 1 change from baseline to week 16 was not significantly different between reslizumab and placebo, and no significant relationship was detected between treatment, baseline blood eosinophils and change in FEV 1 . In the subgroup of patients with baseline eosinophils < 400 cells/μL, patients treated with reslizumab showed no significant improvement in FEV 1 compared with those receiving placebo. In the subgroup with eosinophils ≥ 400 cells/μL, however, treatment with reslizumab was associated with much larger improvements in FEV 1 , ACQ-7, rescue SABA use, and FVC compared with the placebo group. Reslizumab was well tolerated, with fewer overall adverse events compared with placebo (55% vs 73%). Conclusions Reslizumab was well tolerated in patients with inadequately controlled asthma. Clinically meaningful effects on lung function and symptom control were not seen in patients unselected for baseline eosinophils. Trial Registry ClinicalTrials.gov; No.: NCT01508936; URL: www.clinicaltrials.gov
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Eosinophilic Inflammation in Asthma
Bousquet, J., Chanez, P., Lacoste, J. Y., Barnéon, G., Ghavanian, N., Enander, I., Venge, P., Ahlstedt, S., Simony-Lafontaine, J., Godard, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010113231505 · Cited by 2,499
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Castro, M., Zangrilli, J., Wechsler, M. E., Bateman, E. D., Brusselle, G. G., Bardin, P., Murphy, K., Maspero, J. F., O'Brien, C., & Korn, S. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00042-9 · Cited by 1,182
Self-citationReslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study
Castro, M., Mathur, S., Hargreave, F., Boulet, L.-P., Xie, F., Young, J., Wilkins, H. J., Henkel, T., & Nair, P. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0396oc · Cited by 716
Shankar, G., Devanarayan, V., Amaravadi, L., Barrett, Y. C., Bowsher, R., Finco-Kent, D., Fiscella, M., Gorovits, B., Kirschner, S., Moxness, M., et al. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.09.020 · Cited by 613
Distinguishing severe asthma phenotypes
Miranda, C., Busacker, A., Balzar, S., Trudeau, J., & Wenzel, S. E. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.10.041 · Cited by 586
The Relationship between Airways Inflammation and Asthma Severity
LOUIS, R., LAU, L. C. K., BRON, A. O., ROLDAAN, A. C., RADERMECKER, M., & DJUKANOVIĆ, R. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.1.9802048 · Cited by 571
Kips, J. C., O'Connor, B. J., Langley, S. J., Woodcock, A., Kerstjens, H. A. M., Postma, D. S., Danzig, M., Cuss, F., & Pauwels, R. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-525oc · Cited by 494
Castro, M., Wenzel, S. E., Bleecker, E. R., Pizzichini, E., Kuna, P., Busse, W. W., Gossage, D. L., Ward, C. K., Wu, Y., Wang, B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70201-2 · Cited by 488
Takatsu, K., & Nakajima, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.001 · Cited by 320
Malinovschi, A., Fonseca, J. A., Jacinto, T., Alving, K., & Janson, C. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.007 · Cited by 268
Zeiger, R. S., Schatz, M., Li, Q., Chen, W., Khatry, D. B., Gossage, D., & Tran, T. N. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.06.005 · Cited by 243
Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes
Westerhof, G. A., Korevaar, D. A., Amelink, M., de Nijs, S. B., de Groot, J. C., Wang, J., Weersink, E. J., ten Brinke, A., Bossuyt, P. M., & Bel, E. H. (2015) · European Respiratory Journal · doi:10.1183/09031936.00012415 · Cited by 167
Gupta, S., Devanarayan, V., Finco, D., Gunn, G. R., Kirshner, S., Richards, S. M., Rup, B. J., Song, A., & Subramanyam, M. (2011) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2011.03.038 · Cited by 144
Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma
Ulrik, C. S. (1995) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.1995.tb00024.x · Cited by 140
Egan, R. W., Athwal, D., Bodmer, M., Carter, J., Chapman, R. W., Choua, C.-C., Coxa, M., Emtage, S., Fernandez, X., Genatt, N., et al. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300502 · Cited by 112
High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma
Fowler, S. J., Tavernier, G., & Niven, R. M. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.09.034 · Cited by 100
Walsh, G. M. (2009) · PubMed · Cited by 65
Qiu, Z. J., Ying, Y., Fox, M., et al. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.09.013 · Cited by 24
The best laid schemes of airway repair
Rawlins, E. L., & Giangreco, A. (2014) · European Respiratory Journal · doi:10.1183/09031936.00088014 · Cited by 22
Cited by
Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
Lambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Holguin, F., Cardet, J. C., Chung, K. F., Diver, S., Ferreira, D. S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., Knight, S., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00588-2019 · Cited by 629
König, I. R., Fuchs, O., Hansen, G., von Mutius, E., & Kopp, M. V. (2017) · European Respiratory Journal · doi:10.1183/13993003.00391-2017 · Cited by 572
McGregor, M. C., Krings, J. G., Nair, P., & Castro, M. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1944ci · Cited by 432
Metadata
- Authors
- Corren, J., Weinstein, S., Janka, L., Zangrilli, J., & Garin, M.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 150
- Issue
- 4
- Pages
- 799-810
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2309688181
- Cited by
- 388
- References
- 25
- FWCI
- 41.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.